


# 2026 American Society of Clinical Oncology (ASCO) Annual Meeting



 Saturday, May 30, 2026

**Title:** The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): Secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAGon study.

**Lead Author:** Hans Gelderblom

**Abstract:** 11504

**Oral presentation:** Saturday, May 30, 2026 (Session time: 4:12 PM – 4:24 PM CDT)

**Title:** Phase 1 study of the tetravalent death receptor 5 agonist ozekibart (INBRX-109) combined with chemotherapy in locally advanced or metastatic, unresectable colorectal adenocarcinoma (CRC).

**Lead Author:** Hazel Lote

**Abstract:** 3533

**Poster presentation:** Saturday, May 30, 2026 (Session time: 9:00 AM – 12:00 PM CDT)

 [ASCO 2026\\_ChonDRAGon Secondary Endpoints\\_Abstract](#)  
(167 KB)

 [ASCO 2026\\_Ozekibart in CRC Updated Data\\_Abstract](#)  
(150 KB)

 [ASCO 2026\\_INBRX-109 CRC Data Update\\_Poster\\_Lote](#)  
(1.8 MB)

 [ASCO 2026\\_ChonDRAGon Secondary Endpoints\\_Oral Presentation\\_Gelderblom](#)  
(902 KB)

<https://inhibrxbiosciences.investorroom.com/events-and-presentations?item=57>